|FOXFIREGlobal||* This study has finished *|
|Full title:||Assessment of Overall Survival of FOLFOX6m plus SIR-Spheres microspheres versus FOLFOX6m alone as first-line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma in a randomised clinical study.|
|Cancer type:||Metastatic Colorectal|
|The aim of this study was to provide additional data to two other studies (FOXFIRE & SIRFLOX) assessing the effectiveness of SIR Spheres microspheres. The aim of this study, and of the pooled data, was to assess the efficacy of first line combination therapy with SIR-Spheres microspheres on overall survival.
Similar to SIRFLOX, this study involved the administration of chemotherapy and implantation of SIR-Spheres, a treatment being developed for colorectal cancer that has spread to the liver. SIRT is a form of treatment that has been designed to selectively deliver radiation to the cancer within the liver. SIRT involves injecting very small radioactive particles (SIR-Spheres microspheres) into the blood stream of the liver. The administration of SIR-Spheres microspheres is a form of radiotherapy and is designed to destroy cancer in the liver. This form of treatment has been used in a number of clinical trials and has been approved for use in the treatment of liver cancer in Australia and other countries.
The main purpose of this study was to find out if the combination of SIRT and chemotherapy gives improved outcomes over chemotherapy alone for this group of patients.
Approximately 200 patients took part in the study at institutions in New Zealand, Australia, the United States and across the globe.
Further information available at www.sirflox.com
· Palmerston North
|Lead Investigator:||Professor Michael Findlay|
|Contact:||Lindsey Wylde (firstname.lastname@example.org)|
|Trial Registry reference:||NCT01721954 (click for more details)|